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Background and aims: The causative molecular pathways underlying the pathogenesis of coeliac disease
are poorly understood. To unravel novel aspects of disease pathogenesis, we used microarrays to
determine changes in gene expression of duodenal biopsies.
Methods: cDNA microarrays representing 19 200 genes were used to compare gene expression profiles
of duodenal biopsies from 15 coeliac disease patients with villous atrophy (Marsh III) and seven control
individuals with normal biopsies (Marsh 0). In addition, the specific effect of gluten was studied by
comparing the expression profiles of Marsh III lesions of seven patients exposed to gluten with four patients
on a gluten free diet.
Results: Comparing Marsh III with Marsh 0 lesions identified 109 genes that differed significantly
(p,0.001) in expression levels between patients and controls. A large number of these genes have
functions in proliferation and differentiation pathways and might be important for correct development of
crypt-villous units. Alterations in these pathways may lead to the characteristic hyperplasia and villous
atrophy seen in coeliac disease. The analyses also revealed 120 differentially expressed genes (p,0.005)
when comparing patients on a gluten free diet with those exposed to gluten. These genes further strengthen
our observation of increased cell proliferation in the presence of gluten.
Conclusions: Our study provides new candidate genes in the pathogenesis of coeliac disease. Based on
our results, we hypothesise that villous atrophy in coeliac disease patients is due to failure in cell
differentiation. These genes are involved in pathways not previously implicated in coeliac disease
pathogenesis and they may provide new targets for therapy.
C
oeliac disease (OMIM 212750) is a chronic inflamma-
tory enteropathy caused by lifelong intolerance to
gluten in genetically predisposed individuals. When
gluten, the main protein present in wheat, rye, and barley,1 is
ingested by individuals expressing human leucocyte antigen
(HLA)-DQ2 and/or -DQ8 heterodimers,2 it provokes a mis-
directed immune response in the small intestine where
gluten is absorbed. This immune response leads to a series of
histological changes resulting in lymphocytosis, crypt hyper-
plasia, and villous atrophy. These histological abnormalities,
which were documented by Marsh in 1992,3 are characteristic
of this disease and explain some of the clinical symptoms of
coeliac disease patients. Treatment of coeliac disease consists
of a lifelong gluten free diet, resulting in clinical recovery and
histological normalisation of the intestine.
Coeliac disease is a multifactorial disorder for which both
genetic and environmental factors are required for the
disease phenotype to develop.4 The molecular pathways
responsible for the disease pathogenesis are currently only
partly defined.5 So far only one genetic factor has been
identified, the HLA-DQA and -DQB gene cluster on chromo-
some 6.2 Although many attempts are underway to identify
the other genetic factors involved in coeliac disease, trad-
itional genetic mapping studies face serious limitations in
identifying the full repertoire of susceptibility genes due to
the small contribution of each individual susceptibility gene
and the complex interplay between genetic and environ-
mental factors. Genomics technologies, such as cDNA
microarrays, are expected to provide additional insight into
the molecular and cellular aspects of diseases.
Coeliac disease is a unique disease as the environmental
factor, gluten, that triggers the disease is known and can be
easily manipulated in vivo as well as in vitro. Moreover, the
site of the lesion is easily accessible and small intestinal
biopsies need to be taken from coeliac disease patients as part
of the standard diagnostic procedure. In order to expand our
understanding of the pathogenesis of coeliac disease, we set
out to perform cDNA microarray analysis on a set of well
characterised duodenum biopsies from coeliac disease
patients with classic histopathology (Marsh III (MIII)) and
control individuals (Marsh 0 (M0)). Microarray analysis is a
powerful technique that allows the study of the level and
pattern of expression of thousands of genes simultaneously.6
We first thought that comparing MIII with M0 biopsies
might lead to the discovery of genes involved in the immune
response to gluten and the long term tissue destruction
seen in the small intestine of coeliac disease patients.
Subsequently, we investigated the molecular changes that
occur in MIII biopsies by comparing a collection of MIII
biopsies from individuals who were on a gluten free diet with
those on a gluten containing diet (that is, exposed to gluten).
We report two sets of genes that have not previously been
associated with the pathogenesis of coeliac disease. Our
results imply a role for novel candidate genes involved in the
maintenance of the intestinal villi. As some of these genes
map to chromosomal regions implicated in genetic mapping
studies, they may represent possible causal candidate genes.
The combination of well characterised intestinal biopsies
and cDNA microarrays is a unique method of studying the
molecular and cellular events taking place in the initiation
Abbreviations: HLA, human leucocyte antigen; M, Marsh; Th, T helper;
RT-PCR, reverse transcription-polymerase chain reaction; IFN,
interferon; IL, interleukin; APC, antigen presenting cells
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and further progression towards the mucosal transformation
seen in coeliac disease. It has not yet been applied to this
disease.
MATERIALS AND METHODS
Patients
Intestinal biopsies from 15 coeliac disease patients were
included in the study. All biopsies showed MIII histology and
were evaluated by one pathologist (JWRM) according to the
modified UEGW criteria.7
Seven patients (patients 1–7, table 1) suspected of having
coeliac disease were on a gluten containing diet when MIII
villous atrophy was histologically confirmed.
Another four coeliac disease patients (patients 8–11,
table 1) were on a gluten free diet for a year and reported
total clinical recovery although their intestines still showed
MIII characteristics. A slight histological improvement was
reported. In addition, biopsies were taken from the last
group of four patients (patients 12–15, table 1), who were
refractory coeliac disease type I patients.8 Biopsies of these
four refractory coeliac disease type I patients showed MIII
histology and no clinical improvement8 despite the fact that
they were on a strict gluten free diet. A team of dieticians
monitored compliance to the diet in all patients on a gluten
free diet.
In addition, duodenum biopsies from seven individuals
who had an endoscopic examination for other reasons were
used as control samples. The histology of these tissue biopsies
was completely normal (M0). Characteristics of the coeliac
disease patients and controls included in this study are
summarised in table 1.
The Medical Ethical Committee of the University Medical
Centre of Utrecht approved the study. All patients, or the
parents of paediatric patients, included in the study gave
written informed consent.
Biopsy sampling and RNA isolation
For each individual, two to three biopsies (15–20 mg) were
taken from the proximal duodenum by spike forceps
endoscopy. Fresh tissue samples were snap frozen and stored
in liquid nitrogen. Frozen biopsies were homogenised in
TRIzol with glass beads of 1 mm diameter using a Mini-
BeadBeater (BioSpec Products, Inc, Bartlesville, Oklahoma,
USA), and total RNA was isolated using TRIzol (Gibco/Life
Technologies, Rockville, Maryland, USA) following the
manufacturer’s protocol. The quality and quantity of the
RNA samples was determined using a 2100 Agilent
Bioanalyzer (Agilent Technologies, Palo Alto, California,
USA). Biopsies yielded an average of 3.6 mg of RNA/mg of
tissue.
Microarray hybridisation
The seven controls and 15 coeliac disease samples were
analysed by hybridisation screening of cDNA microarrays
obtained from the University Health Network of Toronto,
Ontario (Canada). Two different releases of slide sets, 19k2
and 19k3, containing 19 200 genes printed in duplicate on
two glass slides were used for the experiments.
First strand cDNA was prepared from 10 mg of total RNA
from biopsies and labelled with Cy3, as described by Van
de Peppel and colleagues.9 A surgical specimen from the
small bowel was used to generate a Cy5 labelled cDNA
probe for use as a reference in all coeliac disease and control
hybridisations. Between 200 and 300 ng of labelled cDNA
from the biopsies and reference tissues were used for a single
set of slides for overnight hybridisation. Slides were scanned
in a ScanArray 4000 XL (Packard BioScience, Boston,
Massachusetts, USA).
An MIAME compliant10 downloadable dataset and full
details of the protocols are available at http://humgen.
med.uu.nl/publications/CD/Microarrays/Diosdado_1.html or
http://www.ebi.ac.uk/arrayexpress/, experiment accession
No E-MEXP-42.
Image and data analysis
The scanned images were subjected to image analysis
using the Dearray suite11 for IPLab SPECTRUM software
(Scanalytics, Inc., Fairfax, Virginia, USA). The software, in a
Table 1 Characteristics of coeliac disease, refractory gluten free diet type I patients, and
controls included in the study
Sample Age/Sex Diagnosis Biopsy status` GFD HLA typing Slide type1
1 18/F CD patient* MIIIb No DQ2+/DQ82 19k2
2 3/M CD patient MIIIb No DQ2+/DQ82 19k3
3 54/F CD patient MIIIc No DQ2+/DQ82 19k3
4 33/F CD patient MIIIa No DQ2+/DQ82 19k3
5 2/F CD patient MIIIc No DQ2+/DQ82 19k3
6 79/F CD patient MIIIb No DQ2+/DQ82 19k3
7 38/M CD patient MIIIa No DQ2+/DQ82 19k2
8 61/M CD patient MIIIb Yes DQ2+/DQ82 19k3
9 40/M CD patient MIIIb Yes DQ2+/DQ82 19k3
10 61/F CD patient MIIIa Yes DQ2+/DQ82 19k3
11 70/M CD patient MIIIa Yes DQ2+/DQ82 19k3
12 51/F RCD type I patient MIIIa Yes DQ2+/DQ82 19k3
13 29/F RCD type I patient MIIIb-c Yes DQ2+/DQ8+ 19k3
14 84/F RCD type I patient MIIIa Yes DQ2+/DQ82 19k3
15 72/F RCD type I patient MIIIa Yes DQ2-/DQ82 19k3
16 32/F Control M0 No DQ2+/DQ8+ 19k2
17 40/F Control M0 No DQ2-/DQ82 19k3
18 51/F Control M0 No n/d 19k3
19 60/F Control M0 No n/d 19k3
20 36/F Control M0 No DQ2-/DQ82 19k2
21 32/F Control M0 No n/d 19k2
22 33/F Control M0 No DQ2-/DQ8+ 19k2
*CD patient, coeliac disease patient; RCD patient, refractory gluten free diet type I patient.
`Histology was reviewed by the same pathologist (JWRM). Biopsies were classified according to the UEGW
criteria.
GFD, gluten free diet.
1Two releases of microarray slides, 19k2 and 19k3, from the University Health Network, Toronto, Ontario
(Canada) were used for hybridisations.
Microarray screen for coeliac disease pathogenesis 945
www.gutjnl.com
semi-automatic manner, identifies the fluorescent spots,
subtracts the local background, and determines a quality
score for each spot based on the spot’s intensity, size, local
background, and uniformity of intensity within the spot.12
Based on these parameters, a quality score is assigned to each
individual spot. All spots with a quality score .0.01 were
selected for further processing.
To correct for differences in the efficiencies between the
Cy3 and Cy5 channel, a method of global normalisation was
applied. The quantified signal intensity for the entire array in
both the Cy3 and Cy5 channels was averaged and equalised
by applying a normalisation factor. Subsequently, this
normalisation correction was applied to each individual spot
and the red to green ratio was calculated.12 As genes are
spotted in duplicate, the average of the 10log of the signal of
each of the two copies of the same gene was calculated only
when the quality score for both genes was .0.01. When only
one copy of the gene had a quality score .0.01, only the level
of expression of that gene copy was used.
Data analysis was performed with the GeneSpring package,
version 4.2.1 (Silicon Genetics, Redwood City, California,
USA). Genes whose expression was significantly different
between two groups of biopsy samples were selected from the
genes present on the slides by applying a Welch t test. Cluster
analysis was performed using a supervised cluster algorithm.
Gene analysis
To further define the biological function of the selected genes,
a homemade Java tool database was developed (Franke et al,
in press) for data storage, gene classification, and gene
analysis. This database also contains information on selected
genes such as GeneBank accession No, Locus Link ID,
chromosomal location, Emsembl ID, Unigene information,
Gene Ontology, and GeneCards ID.
Data validation by real time RT-PCR
A selection of genes that showed altered expression in the
microarray analysis was re-examined by real time reverse
transcription-polymerase chain reaction (RT-PCR) to validate
the changes observed in an independent manner. Firstly,
cDNA was generated from 1 mg of total RNA using the High
Capacity cDNA Archive Kit. PCR cycling was performed on a
7900HT Sequence Detection System in 25 ml SYBR Green PCR
Master Mix using 25 ng of reverse transcribed RNA. Target
genes were tested for using Assay-on-Demand Gene Expres-
sion products. The GUSB gene was used as an endogenous
reference to control for expression independent sample to
sample variability. Relative expression was determined from
the obtained Ct values and the 22DDCt method.13 All equip-
ment and reagents were purchased from Applied Biosystems
(Foster City, California, USA) and used according to their
protocols. Six genes (ALDOB, IL2RB, PDE7B, TM4SF4, TXN,
and TYK2), together with the GUSB reference, were tested in
duplicate on pooled cDNA from M0 normal controls (n=16)
and MIII coeliac patients (n=15). The pooling method was
used only after we had assessed that the mean of the data
obtained with ALDOB tested on individual samples was
similar to that of the pooled samples (table 2). This pooling
method was in agreement with our experiences with various
other genes not directly related to this study.
RESULTS
Identification of genes differentially expressed in MIII
biopsies versus M0 biopsies
In order to identify genes involved in the pathogenesis and
therefore in the inflammatory and immune response evoked
by gluten and leading to the tissue destruction observed in
the duodenal biopsies of coeliac disease patients, the expres-
sion profiles of 15 MIII biopsies from patients were compared
with seven M0 biopsies from control individuals. All biopsy
RNA samples from MIII coeliac disease patients, including
four refractory coeliac disease type I samples, were hybridised
onto cDNA microarrays. A Welch t test with a threshold p
value of ,0.001 revealed no differentially expressed genes
when comparing MIII refractory coeliac disease type I bio-
psies with MIII coeliac disease biopsies (data not shown). As
these two groups could not be distinguished based on their
expression levels, they were treated as a single group based
on their histological characteristics.
From all 19 200 genes present on the arrays, 10 674 had
sufficient data for comparison (that is, genes with a quality
score .0.01). A Welch t test with a threshold of p,0.001 was
applied to the data set and 109 genes were identified to be
differentially expressed between MIII and M0 biopsy sam-
ples. Approximately 11 genes were expected by chance alone.
A distance measurement was used to define the similarity of
the expression profiles for both the 22 samples and the 109
genes, and was depicted in a two dimensional hierarchical
dendrogram (fig 1A). The hierarchical cluster analysis
revealed two branches clearly separating the M0 and MIII
biopsies, with the exception of control No 19 that clustered
with the group of patient samples.
Of these 109 genes, 76 (69.7%) had an increased level of
expression in coeliac disease patients versus controls, and 33
genes (30.3%) had a decreased level of expression in coeliac
disease patients versus controls. The molecular function was
known or could be predicted for 46 of these 109 genes
(table 3).
Some of the differentially expressed genes result from the
histological changes but a significant number of them result
from the inflammatory response seen in MIII lesions of
coeliac disease patients. The results from these experiments
are consistent with the widely accepted T helper (Th)1
response.14 Although this observation in itself adds little new
insight, it does replicate previous independent findings.
Hence these observations support our results and thereby
validate microarray technology as a useful tool in providing
new insight into the pathogenesis of coeliac disease.
Although the key cytokines interferon (IFN)-c and tumour
necrosis factor a were not present on our slides, real time RT-
PCR of the IFNG gene showed extremely high levels of
expression of ,30-fold in MIII biopsies versus M0 biopsies.
Stimulation of the interleukin (IL)-2 signalling pathway
was further suggested by increased expression of the IL-2
receptor beta (IL-2RB) gene which was validated by real-time
RT-PCR (table 2), a member of the RAS oncogene family
(RAB1B), chromosome 20 open reading frame 64 gene
(C20orf64), and the RAP1, GTP-GDP dissociation stimulator
1 gene (RAP1GDS1). Furthermore, the nuclear factor kB
pathway seems to be induced, as suggested by upregulation
Table 2 Relative levels of average gene expression
levels in Marsh III coeliac patients versus normal controls,
as determined by microarray hybridisation and validation
by real time reverse transcription-polymerase chain
reaction
Gene Microarray RT-PCR
ALDOB* 0.51 0.23
ALDOB 0.51 0.28
IL2RB2 1.36 1.28
PDE7B 0.64 0.94
TM4SF4 0.50 0.12
TXN 1.26 1.33
TYK2 1.30 0.99
Real time RT-PCR data for ALDOB are indicated as the mean of individual
samples* and as pooled samples of normal controls (n = 16) and Marsh
III coeliac patients (n = 15). The other genes were tested only on pools.
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of the thioredoxin (TXN) gene and the lymphocyte cytosolic
protein 1 (LCP1) gene. Genes involved in complementary
functions, such as complement component 8 b polypeptide
(C8B) and the H factor 1 (HF1), were downregulated,
suggesting depletion of complement components.
Upregulation of both the TXN and the macrophage scaven-
ger receptor 1 (MSR1) genes in MIII versus M0 provides
evidence for the presence of active macrophages at the lesion
site. MSR1 is expressed by antigen presenting cells (APC) and
mediates activation of T cells and promotes adhesion of
activated B cells.15 16 It has also been suggested that MSR
class A is involved in the breakdown of the T cell self tole-
rance in mice.17 18 TRX enhances the immune response by
facilitating both a microenvironment for APCs and for T cell
interaction. It has been further proposed that TRX acts as
coadjuvant in cytokine mediated lymphocyte proliferation
between the APC which presents the gluten to the CD4+ T
cells.19 Upregulation of TRX was validated by real time RT-
PCR (table 2).
Many genes coding for proteins involved in lipid metabo-
lism and cholesterol homeostasis, such as ATP binding
cassette, subfamily A, member 7 (ABCA7), apolipoprotein
A-II (APOA2), and diaphorase (NADH) (DIA1), were upre-
gulated in MIII biopsies whereas hydroxy-delta-5-steroid
dehydrogenase, 3 beta- and steroid 1 (HSD3B1) was down-
regulated. Expression studies have shown that cd T cells
differentially express a large number of genes involved in
lipid and cholesterol homeostasis, implying that such cells
may be involved in these mechanisms.20 One of the
histological characteristics of MIII coeliac disease biopsies is
the presence of high numbers of intraepithelial cd T cells.3
Hence these results may reflect the increased number of cd
T cells in the intestines of coeliac disease patients.
Alternatively, increased expression of lipid and cholesterol
genes may point to increased biosynthesis of lipid bilayers. In
both cases, upregulation of these genes may be due to an
increase in the number of cells and not to upregulation ‘‘per
cell’’ of these genes.
Downregulation of the transmembrane 4 superfamily
member 4 gene (TM4SF4), which by real time RT-PCR
turned out to be down-regulated eightfold (table 2), and
upregulation of the retinol binding protein 4 gene (RBP4), are
both consistent with increased proliferation of cells in MIII
biopsies. Also, upregulation of annexin A6 (ANXA6), synap-
topodin (KIAA1029), and the solute carrier family 9 isoform 3
regulatory factor 1 (SLC9A3R1) genes suggests an increased
number of cells in early differentiation.
In summary, the differentially expressed genes point
towards an increased number of cd T cells and macrophages
at the lesion site, a Th1 response, and increased cell
proliferation.
Differential gene expression in MIII biopsies in
response to gluten withdrawal
To identify genes specifically involved in the response to the
environmental trigger gluten, MIII biopsies were subse-
quently divided into two groups. Four MIII biopsies from
coeliac disease patients who were on a gluten free diet for one
year were compared with seven MIII biopsies from patients
who were following a gluten containing diet at the time of
biopsy. The four biopsies of the refractory coeliac disease type
I patients were excluded from this analysis as these patients
do not show clinical and histological improvement on gluten
withdrawal, and so different molecular events may be
occurring in their biopsies.
Figure 1 (A) Hierarchical clustering dendrogram of duodenal genes from Marsh III (MIII) and Marsh 0 (M0) biopsies. Clustering of 109 genes across
22 samples clusters the seven control samples (blue bar) separately from the 15 coeliac disease patients (orange bar). Each column represents a coeliac
disease (MIII) or a control (M0) sample and each row represents an individual gene. For each gene, a green signal represents underexpression, black
signals denote similarly expressed genes, a red signal represents overexpressed genes, and grey signals denote missing data. Information on these
genes can be found in table 3 and on the website http://humgen.med.uu.nl/publications/CD/Microarrays/Diosdado_1.html. (B) Hierarchical
clustering dendrogram of duodenal genes from MIII biopsies with or without exposures to gluten. Clustering of 120 genes across 11 samples clusters
the seven samples of coeliac disease patients following a gluten containing diet (blue bar) separately from the four coeliac disease patients on a gluten
free diet (orange bar). Each column represents a sample and each row represents an individual gene. For each gene, a green signal represents
underexpression, black signals denote similarly expressed genes, a red signal represents overexpressed genes, and grey signals denote missing data.
Information on these genes can be found in table 3 and on the website http://humgen.med.uu.nl/publications/CD/Microarrays/Diosdado_1.html.
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A Welch t test was applied to 11 938 genes that had
sufficient data for comparison; 120 genes showed differential
expression at a threshold p value ,0.005 (table 4). We are
aware of the limitations of this small number of samples.
This experimental design is therefore less robust than the
MIII versus M0 comparison as the number of genes to
be expected by change alone would be 60. Although the
data should be interpreted with care, the general picture
that emerges from the data may give inroads into the effect
of gluten on the intestine. A two dimensional hierarchical
cluster showed a dendrogram tree (fig 1B) in which the
four patients on a gluten free diet clearly clustered sepa-
rately from the seven patients on a gluten containing
diet.
Table 3 Annotated genes differentially expressed in Marsh III (MIII) versus Marsh 0 (M0), grouped according to their function*
Gene symbol Gene name LocusLink ID
Chromosome
location
Ratio
MIII/M0
Immune response related
C8B Complement component 8, beta polypeptide 732 1p32.1 0.67
HF1 H factor 1 (complement) 3075 1q31.3 0.80
MSR1 Macrophage scavenger receptor 1 4481 8p22 1.25
TXN Thioredoxin 7295 9q31.3 1.26
IL2RB Interleukin 2 receptor b 3560 22q13.1 1.36
Chemokines, cytokines, and growth factors
BTN2A1` Butyrophilin, BTF1 precursor 11120 6p22.2 1.18
Inflammatory mediators
PRG1 Proteoglycan 1, secretory granule 5552 10q22.1 1.21
Cancer related genes
DKFZP586A011 Cervical cancer 1 proto oncogene 25875 12q13.13 0.72
C20orf64 Chromosome 20 open reading frame 64 112858 20q13.12 1.30
Structural related genes
TM4SF4 Transmembrane 4 superfamily member 4 7104 3q25.1 0.50
IGFBP7 Insulin-like growth factor binding protein 7 3490 4q12 0.73
EPB42 Erythrocyte membrane protein band 4.2 2038 15q15.2 0.79
BTN2A1` Butyrophilin, BTF1 precursor 11120 6p22.2 1.18
SLC9A3R1 Solute carrier family 9, isoform 3 regulatory
factor 1
9368 17q25.1 1.20
RBP4 Retinol binding protein 4, interstitial 5950 10q23.33 1.24
KIAA1029 Synaptopodin 11346 5q33.1 1.43
Signal transduction
PPP3CB Calcineurin A beta 5532 10q22.2 0.76
RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 5910 4q23 1.22
RAB1B RAB1B, member RAS oncogene family 81876 11q13.3 1.23
ANXA6 Annexin A6 309 5q33.1 1.24
LCP1 Lymphocyte cytosolic protein 1 3936 13q14.13 1.30
TYK2 Tyrosine kinase 2 7297 19p13.2 1.30
JFC1 NADPH oxidase related, C2 domain
containing protein
84958 1p35.2 1.34
Metabolic pathways and ion transport
mediators
ALDOB Aldolase B, fructose bisphosphate 229 9q31.1 0.51
PDE7B Phosphodiesterase 7B 27115 6q23.3 0.64
FLJ12899 Pantothenate kinase 3 79646 5q34 0.71
HSD3B1 Hydroxy-delta-5-steroid dehydrogenase,
3 beta- and steroid-1
3283 1p12 0.82
ABCA7 ATP binding cassette, subfamily A, member 7 10347 19p13.3 1.18
APOA2 Apolipoprotein A-II 336 1q23.3 1.21
SRI Sorcin 6717 7q21.12 1.23
GYG2 Glycogenin 2 8908 Xp22.33 1.27
SMUG1 Single strand selective monofunctional uracil
DNA glycosylase
23583 12q13.13 1.29
MRPS22 Mitochondrial ribosomal protein S22 56945 3q23 1.29
KCNQ3 Potassium voltage gated channel, KQT-like
subfamily, member 3
3786 8q24.22 1.30
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+)
polypeptide
477 1q23.2 1.30
DIA1 Diaphorase (NADH) 1727 22q13.2 1.30
Cell cycle regulators and transcription factors
HBP1 HMG-box containing protein 1 26959 7q22.3 0.83
KHDRBS1 Sam 68 10657 1p35.1 1.11
NAP1L4 Nucleosome assembly protein 1-like 4 4676 11p15.4 1.27
C20orf64 Chromosome 20 open reading frame 64 112858 20q13.12 1.30
C21orf66 Chromosome 21 open reading frame 66 94104 21q22.11 1.38
Cell-cell signalling
ECM2 Extracellular matrix protein 2 1842 9q22.31 1.24
RIMS1 Regulating synaptic membrane exocytosis 1 22999 6q13 1.29
GRM3 Glutamate receptor, metabotropic 3 2913 7q21.12 1.37
Protein synthesis
EIF4EBP3 Eukaryotic translation initiation factor 4E
binding protein 3
8637 5q31.3 0.72
EIF2B3 Eukaryotic translation initiation factor 2B,
subunit 3
8891 1p34.1 1.27
*All of the genes can be found at http://humgen.med.uu.nl/publications/CD/Microarrays/Diosdado_1.html.
Ratio of the expression level for each individual gene when comparing MIII coeliac disease biopsies with M0 biopsies. Genes with values ,1 are downregulated;
genes with values .1 are upregulated.
`Genes located in more than one functional group.
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Of these 120 genes, 46 (38.3%) were downregulated and
75 (62.5%) were upregulated in patients on gluten versus
coeliac disease patients refraining from gluten. Functional
annotation was available for 42 of the 120 genes.
Interestingly, the majority of the differentially expressed
genes suggest transcription is enhanced and mitotic activity
is suppressed in MIII coeliac disease patients who refrain
from gluten.
Table 4 Annotated genes differentially expressed in Marsh III (MIII) biopsies with or without gluten, grouped according to
functional pathways*
Gene symbol Gene name LocusLink ID
Chromosome
location
Ratio
gluten2/gluten+
HLA and immune function genes
C5R1 Complement component 5 receptor 1 728 19q13.32 1.14
CD79B CD79B antigen 974 17q23.3 1.14
MAP4K4 Mitogen activated protein kinase kinase
kinase kinase 4
9448 2q11.2 1.31
ITGA4 Integrin, alpha 4 3676 2q31.3 1.39
Chemokines, cytokines, and growth factors
None
Inflammatory mediators
PDE4D Phosphodiesterase 4D, cAMP specific 5144 5q11.2 0.67
AUH` AU specific RNA binding protein 549 9q22.31 0.86
Cancer related genes
DEPC-1 Prostate cancer antigen-1 221120 11p12 0.79
M17S2 Membrane component, chromosome
17, surface marker 2
4077 17q21.31 1.24
RABL2B RAB-like protein 2B 11158 22q13.33 1.35
Structure related genes
ADAMTS9 A disintegrin-like and metalloprotease
with thrombospondin type 1 motif, 9
56999 3p14.1 0.74
ADRM1 Adhesion regulating molecule 1 11047 20q13.33 0.82
KL Klotho 9365 13q13.1 1.11
FN1 Fibronectin 1 2335 2q35 1.30
Metabolic pathways and ion transport mediators
PREP Prolyl endopeptidase 5550 6q21 0.56
PLCB4 Phospholipase C, beta 4 5332 20p12.2 0.79
AUH` AU specific RNA binding protein 549 9q22.31 0.86
RYR3 Ryanodine receptor 3 6263 15q14 1.22
IDH3A Isocitrate dehydrogenase 3, alpha
subunit
3419 15q25.1 1.21
BG1 Lipidosin 23205 15q23 1.21
SLC25A4 Adenine nucleotide translocator 1 291 4q35.1 1.25
CPT1A Carnitine palmitoyltransferase I, liver 1374 11q13.3 1.31
Cell cycle regulators and transcription factors
LOC51174 Delta-tubulin 51174 17q23.2 0.54
KIF5B Kinesin family member 5B 3799 10p11.22 0.76
CCNG1 cyclin G1 900 5q34 0.77
NT5C2 59-nucleotidase, cytosolic II 22978 10q24.32 0.83
ZNF26 Zinc finger protein 26 7574 12q24.33 1.19
POLR2C Polymerase II, RNA subunit C 5432 16q13 1.19
GTF2H1 General transcription factor IIH,
polypeptide 1
2965 11p15.1 1.24
MSI2 Musashi homologue 2 (Drosophila) 124540 17q23.2 1.28
ZNF317 Zinc finger protein 317 57693 19p13.2 1.32
CDC25A Cell division cycle 25A 993 3p21.31 1.46
PPP2R3A Protein phosphatase 2 (formerly 2A),
regulatory subunit B’, alpha
5523 3q22.3 1.49
POLD3 DNA polymerase delta subunit 3 10714 11q13.4 1.58
Signal transduction
SYPL Synaptophysin-like protein 6856 7q22.3 0.79
WAC WW domain containing adapter
with a coiled-coil region
51322 10p12.1 0.83
HNT Neurotrimin 50863 0.86
RGS16 Regulator of G protein signalling 16 6004 1q25.3 1.23
PSCD3 Pleckstrin homology, Sec7, and coiled/
coil domains 3
9265 7p22.1 1.33
CSPG6 Chondroitin sulphate proteoglycan 6
(bamacan)
9126 10q25.2 1.36
Others
Pro-neuregulin-3 precursor 10q23.1 0.69
HSPA6 Heat shock 70 kDa protein 6 3310 1q23.3 0.76
SARM Sterile alpha and HEAT/Armadillo
motif protein, orthologue of Drosophila
23098 17q11.2 1.26
AMSH Associated molecule with the SH3
domain of STAM
10617 2p13.1 1.29
PERQ1 Postmeiotic segregation increased 2-like
12
64599 7q22.1 1.59
HTF9C HpaII tiny fragments locus 9C 27037 22q11.21 1.61
*All of the genes can be found at http://humgen.med.uu.nl/publications/CD/Microarrays/Diosdado_1.html.
Ratio of the expression level for each individual gene between biopsies from MIII coeliac disease patients on a gluten free diet (gluten2) and MIII coeliac disease
patients following a gluten containing diet (gluten+). Genes with values ,1 are downregulated; genes with values .1 are upregulated.
`Genes located in more than one functional group.
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Several of the genes were related to cell division and
cell cycle processes. The cyclin G1 (CCNG1) gene was
downregulated, indicating that less cells go from the G1
to S phase. Both the delta-tubulin (LOC51174) and kinesin
family member 5B (KIF5B) genes were also downre-
gulated. These two genes play a role in spindle forma-
tion. In addition, genes related to transcription such as
general transcription factor IIH, polypeptide 1 (GTF2H1),
polymerase II RNA subunit C (POLR2C), DNA polyme-
rase delta subunit 3 (POLD3), zinc finger protein 26
(ZNF26), and the zinc finger protein 317 (ZNF317) were
all upregulated.
DISCUSSION
Coeliac disease is a chronic inflammatory disorder trig-
gered by dietary gluten that shows major manifesta-
tions in the small intestine although other organ systems
may also be involved. Coeliac disease is an HLA associated
disease and over the past years our understanding of the
role of both HLA-DQ2 and -DQ8 molecules and gluten
polypeptides has been enhanced tremendously.2 Never-
theless, a detailed understanding of the molecular events
that take place in the intestine of genetically susceptible
individuals is lacking, as well as insight into the order
in which the events occur and other genetic factors that
are known to be important determinants of the disease.
To unravel novel aspects of the pathogenesis of coeliac
disease, cDNA microarray technology was used to moni-
tor expression of thousands of genes simultaneously. The
results from this study confirm earlier studies that coeliac
disease is a Th1 mediated disease,4 21 as evidenced by
upregulation of the IL-2 pathway. Interestingly, novel
genes are being identified that have not been proposed
previously as being important determinants of the path-
ogenesis of coeliac disease. These genes yield new insights
into the molecular processes underlying the flattened
mucosa.
Prolyl endopeptidase
The most notable gene differentially expressed in a com-
parison of coeliac disease patients on a gluten containing
diet versus those on a gluten free diet, is prolyl endopep-
tidase (PREP). The PREP gene encodes a cytosolic prolyl
endopeptidase that efficiently hydrolyses proline rich frag-
ments such as gliadin. PREP is upregulated in coeliac
disease patients on a gluten containing diet compared with
patients adhering to a gluten free diet. Furthermore, its
levels of expression stay elevated in controls. Interestingly,
this gene was also shown to be upregulated in seven con-
trol samples not on a gluten free diet compared with four
biopsies from coeliac disease patients on a gluten free diet
(p,0.003) and, to a lesser extent, when compared with
the four refractory coeliac disease samples on a gluten free
diet (p,0.025). This observation indicates that it is the
presence of gluten in the intestine which modulates
expression of this gene. It has been hypothesised that prolyl
endopeptidase cleaves gliadin in small fragments in the
intestine.22 We hypothesise that, in coeliac disease patients,
the activity of this molecule may be impaired and therefore
it does not cut gliadin into sufficiently small fragments
to create motifs long enough to be recognised by reactive
T cells.22 It has been proposed that a bacterial prolyl
endopeptidase from Flavobacterium memningoseticum may be
a target for future treatment of coeliac disease patients.23
Further research should be done in order to elucidate the
mechanisms controlling activation and expression of this
protein in the intestines of normal and coeliac disease
patients.
Molecular mechanisms controlling hyperplasia and
villous atrophy in MIII biopsies
Enterocytes, one of the main components of the villous,
arises from pluripotent stem cells located in the base of the
intestinal crypts. When these pluripotent stem cells stop
dividing, they complete their programme of differentiation
and start migrating towards the apical part of the villous.
Non-dividing epithelial cells located in the crypts of the small
intestine that are ready to migrate and differentiate express
the TM4SF4 gene.24 In vitro studies have suggested that
TM4SF4 plays a crucial role in regulation of proliferation and
differentiation along the crypts by inhibiting proliferation of
cells at the boundary of the crypt and villous. We observed an
eightfold decrease in the level of expression of the TM4SF4
gene in MIII biopsies of coeliac disease patients versus M0
biopsies of controls, implying a block in early differentiation
and failure to complete villous maintenance. Furthermore,
increased expression of the RBP4 gene and significant
upregulation (p,0.01) of the Eph related receptor tyrosine
kinase B3 (EphB3) gene in MIII versus M0 biopsies was
observed. EphB3 has recently been shown to be tightly
regulated by the Wnt cascade and it has been suggested that
this gene may play a decisive role in controlling not only
proliferation and differentiation but also migration and
location of cells along the crypts.25
Given these results, we propose that stem cells of the small
intestinal crypts start proliferating but do not receive a signal
to start differentiation, leading to the formation of undiffer-
entiated hyperplastic crypts and subsequently villous atro-
phy. This theory is further substantiated by results from the
second experiment in which MIII lesions with or without
exposure to gluten were compared. The presence of gluten
leads to increased mitotic activity, suggesting many prolifer-
ating cells. As soon as gluten is withdrawn from the diet,
mitotic activity diminishes, suggesting that cells stop pro-
liferating and, presumably, start differentiating. Although
the histology still shows a MIII lesion, this event might
actually be the first step towards normalisation of the
intestine. We further propose that the separate processes of
crypt hyperplasia and villous atrophy are molecularly inter-
twined and progression through different histological stages
may be regulated by genes implicated in the control of cell
proliferation and differentiation, such as TM4SF4.
So far, the early pathogenic events leading to villous
atrophy have been suggested to be direct effects of cytokines,
such as IFN-c,21 or hypoxia.3 In addition, using an ex vivo
model of fetal gut, Salmela and colleagues recently proposed
that increased levels of metalloproteinases are important
molecules for tissue remodelling and mucosal degradation in
inflammatory bowel disease and coeliac disease.26 However,
none of the 10 metalloproteinase family members, nor two of
its inhibitors that were present on our slides, showed a
significant change in expression level in MIII biopsies of
coeliac disease patients (data not shown), implying that
these molecules may not play a direct role in the tissue
damage in vivo. Until now, all studies have proposed that
villous atrophy is caused by destruction of enterocytes and,
consequently, loss of structure of the villous. We propose
that villous atrophy is not due to destruction of the villous
but rather to the failure of crypt cells to differentiate into
fully differentiated villous cells. As the cells seem to be
capable of continuing proliferation, this might explain crypt
hyperplasia.
We have successfully demonstrated the use of microarrays
as a general approach to studying complex human diseases.
Expression profiles of the selected biopsies propose known
genes that participate in the pathogenesis of coeliac disease
as well as new pathways that may play a potential role in
disease initiation and progression. Our results suggest that
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crypt hyperplasia may be explained by distortion in the ratio
between cell proliferation and cell differentiation of cells
composing the crypt-villi units. Further investigations of the
identified genes are required and will hopefully advance our
understanding of the molecular mechanisms underlying
coeliac disease. Finally, the finding that prolyl endopeptidase
is differentially expressed in coeliac disease patients may
provide new leads for therapy.
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